Trials / Completed
CompletedNCT00569569
Retaane® in Age-Related Macular Degeneration
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Rudolf Foundation Clinic · Academic / Other
- Sex
- All
- Age
- 20 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
The treatment of fibrotic choroidal neovascular lesions with presence of residual peripheral activity in age related macular degeneration currently presents a great challenge. With visual loss threatening, there are only very few therapeutic options. While these patients are neither suitable for laser therapy nor for photodynamic therapy with Verteporfin, antiangiogenic drugs applied intravitreally are now available. Some patients however reject this therapeutic option because of potential complications such as endophthalmitis and the frequency of necessary injections. 20 patients who rejected intravitreal therapy were treated with Anecortave acetate (Retaane®) which was applied as a juxtascleral depot injection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | juxtascleral depot injection of Retaane | juxtascleral depot injection of Retaane |
Timeline
- Start date
- 2006-02-01
- Completion
- 2007-03-01
- First posted
- 2007-12-07
- Last updated
- 2007-12-07
Source: ClinicalTrials.gov record NCT00569569. Inclusion in this directory is not an endorsement.